Bolt biotherapeutics presents results from the phase 1 dose-escalation clinical study of bdc-3042 at aacr annual meeting 2025

Bdc-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events

BDC Ratings Summary

BDC Quant Ranking